CD8A and ovarian carcinoma: Previous studies have demonstrated that extracellular ISG15 not only acts as an immune adjuvant to enhance the anti-tumour immunity of CD8+ T cells, but also activates NK cells and increases their production of IL-2 and IFN-γ cytokines, resulting in the proliferation of ovarian cancer CD8+ T cells.